The proliferation-suppressor role of Sirt3 was confirmed in multiple cancer types, including breast cancer and colon cancer, both in vitro and in vivo[6,18]; it was also reported that Sirt3 could inhibit HCC cell growth through reducing Mdm2-mediated p53 degradation[19]. Here, SIRT3 is linked to hepatocellular carcinoma.